AUTHORS
Hai-xia Zhou, MD, PhD, Shuai Zhang2, Wenjaun Ma, PhD3, Xiuyan Zhang4, Depei Wu Sr, MD5, Yun Zhao, PhD6
AFFILIATIONS
1 The First Affiliated Hospital of Soochow University, Suzhou, China
2 Soochow University, Suzhou, China
3 Soochow University, Suzhou, China
4 Soochow University, Suzhou, China
5 The First Affiliated Hospital of Soochow University, Suzhou, China
6 Soochow University, Suzhou, China
ABSTRACT
Zinc-finger CCCH domain protein 13 (ZC3H13) is a key regulator of m6A methylation that controls cellular stemness, proliferation, and apoptosis, and participates in hematopoietic regulation and tumorigenesis. However, the function and mechanisms of action of ZC3H13 in T-cell acute lymphoblastic leukemia (T-ALL) remain unclear.
In this study, RT-qPCR analysis revealed that ZC3H13 expression was significantly higher in bone marrow cells from T-ALL patients (n = 12) compared with CD3+ cells from normal bone marrow (NBM) of healthy donors (n = 7, P = 0.005). Following the introduction of two independent shRNA sequences targeting ZC3H13 into CD3? cells using a lentiviral vector, ZC3H13 silencing significantly inhibited the proliferation of primary T-ALL cells (63% reduction, 6 days post inoculation, n = 3, P = 0.013), while exerted minimal effects on normal CD3? cells (11% reduction, n = 3, P = 0.685). It is well established that ZC3H13 is required for the nuclear anchorage of METLL3, the catalytic core of the m6A methyltransferase complex. Western blotting analysis revealed that ZC3H13 silencing led to cytoplasmic accumulation of METTL3 and a marked reduction in nuclear localization of METTL3 in Jurkat cells. Consequently, METTL3 silencing significantly inhibited the proliferation (n = 3, P = 0.0042) and colony-forming cell (CFC) production (n=3, P=0.006), demonstrating the critical role of ZC3H13 in maintaining METTL3 nuclear localization in hematopoietic cells for the first time.
To elucidate the mechanism of ZC3H13, we integrated RNA-seq and m6A-MeRIP-seq datasets for comprehensive analysis. RT-qPCR and Western blotting validation revealed that ZC3H13 silencing significantly downregulated HRAS mRNA (n=3, P=0.0067) and protein expression (n=3, P=0.0008) in Jurkat cells. MeRIP-qPCR results confirmed that ZC3H13 silencing significantly reduced m6A modification levels on the HRAS 3’UTR (n=3, P=0.0058). Dual-luciferase reporter assays verified that ZC3H13-mediated regulation of the HRAS fully dependent on m6A modification on its 3’-UTR. Actinomycin D treatment significantly shortened the half-life of HRAS mRNA.
HRAS is a core oncogene regulating cell proliferation and survival. Among its mutants, HRAS G12V represents a frequent activating mutation at codon 12; this mutation locks HRAS protein in a constitutively active conformation to specifically drive malignant proliferation of T-ALL cells. RT-qPCR data showed that HRAS expression was significantly higher in T-ALL cells than that in NBM CD3+ cells. The effective HRAS silencing resulted in significant impaired proliferation of T-ALL cells. Rescue experiments showed that overexpression of HRAS or HRAS G12V effectively rescued the proliferation suppression and impaired CFC production induced by ZC3H13 or METTL3 silencing, establishing the core ZC3H13-METTL3/m6A/HRAS regulatory pathway.
STC-15 is an oral, selective small-molecule inhibitor of METTL3. In T-ALL cell-derived xenograft (CDX) models, STC-15 treatment markedly prolonged the survival of leukemic mice (37 days vs. 44 days, n =7, P=0.0002 estimated by Kaplan-Meier method). Meanwhile, some dosage treatment on immunodeficient mice (n = 6) did not exhibit detectable toxicity. We further evaluated the synergistic effects of STC-15 combined with multiple chemotherapeutic agents. The combination of STC-15 plus vincristine (VCR, synergy score: 9.124) exhibited superior synergistic activity compared with STC-15 combined with daunorubicin (DNR, synergy score: 4.663) or cytarabine (Ara-C, synergy score: 5.457). In patient-derived xenograft (PDX) models, STC-15 combined with VCR significantly prolonged mouse survival (Vehicle : 37 days, STC-15 : 45 days, VCR : 47 days, STC-15 + VCR (combo) : 68 day; STC-15 vs. combo, P < 0.0001; VCR vs. combo, P < 0.0001). Thus, targeting ZC3H13/METTL3 complex provides a promising therapeutic strategy for T-ALL.
In summary, this study demonstrates for the first time that ZC3H13 mediates m6A modification of HRAS mRNA to enhance its stability, and consequently promotes T-ALL progression, which identifies a novel m6A regulatory mechanism in T-ALL, offering novel therapeutic targets and combinatorial chemotherapy strategies.
DISCLOSURES
Yun Zhao, PhD: No relevant conflicts of interest to declare.